ADVFN US – Market Content Editor
-

Nvidia Leadership Crisis Raises Concerns Over AI Semiconductor Earnings and US Export Restrictions
The leadership crisis at Nvidia (NASDAQ:NVDA) has prompted concerns about the wider semiconductor industry, with Lynx Equity Strategies analyst KC Rajkumar warning that uncertainty surrounding artificial intelligence investment and US export policies could affect earnings expectations across the sector. In a research note titled “AI Semis: The Calm Before the Storm,” Rajkumar suggested that investors…
-

Bank of America’s Hartnett Maintains Cautious Market Outlook Until Treasury Yields and Oil Prices Decline
Bank of America strategist Michael Hartnett and his team have maintained a cautious outlook on financial markets, identifying lower Treasury yields, declining oil prices and a weaker US dollar as conditions needed before adopting a more favourable position on risk assets. The strategists said they intend to remain risk-off until crude oil falls below $70…
-

Ranmore Fund Manager Warns of Risks in AI Stocks as Technology Companies Increase Capital Spending
Sean Peche, founder and portfolio manager of Ranmore Fund Management, has expressed a negative outlook on artificial intelligence-related equities, citing rising capital expenditure among major technology companies and concerns that investors may be placing too much emphasis on past share price performance. His comments follow recent volatility in technology stocks, including a decline in the…
-

Nearly 60% of Large Companies Plan to Increase Use of Lower-Cost Open-Weight AI Models, Capgemini Study Finds
Nearly six in ten senior executives at large companies intend to increase their use of open-weight artificial intelligence models over the next 12 months as businesses seek to manage AI spending that has exceeded initial budgets, according to a study published by Capgemini on Thursday. The research found that 59% of executives reported AI expenditure…
-

Chip Sell-Off Drags Nasdaq, Dow Edges Higher
U.S. stocks finished a volatile week on a mixed note Friday, as a renewed sell-off in semiconductor shares pulled the tech-heavy Nasdaq lower while the Dow managed a small gain. Investors continued to digest the fallout from Jensen Huang’s resignation as Nvidia’s CEO, along with a wholesale inflation report that reinforced expectations the Federal Reserve…
-

Heliostar Presents Q3 2026 Financial and Operating Results with Record Mine Operating Earnings and Cash Balance
Q3 2026 Highlights: Vancouver, Canada – Heliostar Metals Ltd. (TSX: HSTR, OTCQX: HSTXF, FRA: RGG1) (“Heliostar” or the “Company”) reported unaudited financial results for the three and nine months ended September 30, 2026 (“Q3”). Results are presented in US dollars, unless otherwise stated. Heliostar Metals Ltd. is a B2i Digital New and Notable company. Its…
-

Equity Metals Advances Silver Queen Towards 2027 PEA as Arlington Emerges as Second Growth Opportunity
Equity Metals Corporation (TSX-V:EQTY) (USOTC:EQMEF) (FSE:EGSD) is continuing to build the foundations for future development at its Silver Queen silver-gold project in British Columbia, with further resource validation work underway and a Preliminary Economic Assessment (PEA) targeted for Q2 2027. Alongside this progress, exploration at the Arlington property is identifying new targets that could provide…
-

VirTra Reports 42% Third-Quarter Revenue Growth to $7.6 Million as Bookings Reach $10.3 Million
VirTra, Inc. (NASDAQ:VTSI), a provider of firearms and use-of-force training simulators, reported a 42% increase in third-quarter 2026 revenue to $7.6 million, compared with $5.3 million in the corresponding period last year, supported by higher government and international sales. The company returned to quarterly profitability, reporting net income of $2.2 million, or $0.19 per diluted…
-

Rezolute Reports Phase 3 upLIFT Study Meets Primary Efficacy Endpoint in Tumor Hyperinsulinism
Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biotechnology company developing treatments for rare metabolic diseases, announced that its ongoing Phase 3 upLIFT study of ersodetug in patients with tumor hyperinsulinism has met its primary efficacy endpoint, based on preliminary data evaluated on November 5, 2026. The open-label study is assessing ersodetug in patients experiencing uncontrolled hypoglycemia associated…
